128 related articles for article (PubMed ID: 19563418)
1. Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy.
Chang SM; Xing RD; Zhang FM; Duan YQ
Oral Dis; 2009 Nov; 15(8):570-2. PubMed ID: 19563418
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer.
Andratschke M; Chaubal S; Pauli C; Mack B; Hagedorn H; Wollenberg B
Anticancer Res; 2005; 25(4):2821-6. PubMed ID: 16080532
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
7. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
[TBL] [Abstract][Full Text] [Related]
8. Serum hyaluronan levels in oral cancer patients.
Xing RD; Chang SM; Li JH; Li H; Han ZX
Chin Med J (Engl); 2008 Feb; 121(4):327-30. PubMed ID: 18304465
[TBL] [Abstract][Full Text] [Related]
9. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
[TBL] [Abstract][Full Text] [Related]
10. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
[TBL] [Abstract][Full Text] [Related]
11. Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients.
Tamaki S; Sanefuzi N; Kawakami M; Aoki K; Imai Y; Yamanaka Y; Yamamoto K; Ishitani A; Hatake K; Kirita T
Hum Immunol; 2008 Feb; 69(2):88-93. PubMed ID: 18361932
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
[TBL] [Abstract][Full Text] [Related]
14. Serum nitric oxide levels in patients with head and neck squamous cell carcinoma.
Kizilay A; Kalcioğlu MT; Ozuğurlu F; Ozyurt H; Aladağ I; Ozturan O; Akyol O
Kulak Burun Bogaz Ihtis Derg; 2007; 17(3):148-51. PubMed ID: 17873505
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
Shang ZJ; Li JR; Li ZB
Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
[TBL] [Abstract][Full Text] [Related]
16. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck.
Hoffmann TK; Sonkoly E; Homey B; Scheckenbach K; Gwosdz C; Bas M; Chaker A; Schirlau K; Whiteside TL
Head Neck; 2007 May; 29(5):472-8. PubMed ID: 17111427
[TBL] [Abstract][Full Text] [Related]
17. [Examination of serum hyaluronic acid level in patients with oral and maxillofacial malignancy].
Xing RD; Chang SM; Duan YQ; Zhang FM; Dong FS
Hua Xi Kou Qiang Yi Xue Za Zhi; 2004 Aug; 22(4):309-11. PubMed ID: 15379314
[TBL] [Abstract][Full Text] [Related]
18. Management of nasopharyngeal salivary gland malignancy.
Schramm VL; Imola MJ
Laryngoscope; 2001 Sep; 111(9):1533-44. PubMed ID: 11568602
[TBL] [Abstract][Full Text] [Related]
19. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma.
Kim CH; Lee JS; Kang SO; Bae JH; Hong SP; Kahng H
Oral Oncol; 2007 Nov; 43(10):1021-5. PubMed ID: 17306605
[TBL] [Abstract][Full Text] [Related]
20. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma.
Yang CZ; Ma J; Luo QQ; Neskey DM; Zhu DW; Liu Y; Myers JN; Zhang CP; Zhang ZY; Zhong LP
J Oral Pathol Med; 2014 Jan; 43(1):28-34. PubMed ID: 23710769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
